| Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review … Y Fujiwara, N Horita, E Adib, S Zhou, AH Nassar, ZULA Asad, A Cortellini, ... The Lancet Oncology 25 (1), 62-75, 2024 | 13 | 2024 |
| Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis Y Suzuki, S Zhou, Y Ota, M Harrington, E Miyagi, H Takagi, T Kuno, ... JNCI Cancer Spectrum 7 (5), pkad069, 2023 | 5 | 2023 |
| Cardiovascular toxicity associated with androgen receptor axis-targeted agents in patients with prostate cancer: a meta-analysis of randomized controlled trials S Zhou, P Alerasool, N Kishi, H Joshi, G Sahni, CK Tsao Clinical Genitourinary Cancer 22 (3), 102066, 2024 | 2 | 2024 |
| Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis S Zhou, N Kishi, P Alerasool, NC Rohs Targeted Oncology, 1-18, 2024 | 1 | 2024 |
| The incidence of thyroid-related adverse events in solid tumors receiving immune checkpoint blockade with curative intent: A meta-analysis. S Zhou, N Horita, T Shao, M Harrington, Y Fujiwara Journal of Clinical Oncology 41 (16_suppl), 2641-2641, 2023 | 1 | 2023 |
| Cutaneous adverse event profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer: A meta-analysis of phase 3 … S Zhou, P Alerasool, N Kishi, NC Rohs Journal of Clinical Oncology 42 (16_suppl), e20049-e20049, 2024 | | 2024 |
| Endocrine adverse events in patients with cancer receiving perioperative immune checkpoint blockade: a meta-analysis of randomized controlled trials S Zhou, N Horita, T Shao, M Harrington, Y Fujiwara Therapeutic Advances in Medical Oncology 16, 17588359241257874, 2024 | | 2024 |
| Letter to the Editor regarding the article" A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer … S Zhou, P Alerasool, CK Tsao Critical reviews in oncology/hematology, 104383, 2024 | | 2024 |
| Tolerability and toxicity profiles of antibody-drug conjugates for the treatment of malignant neoplasms: A meta-analysis of randomized clinical trials. S Zhou, T Kuno, E Miyagi, JD Wright, H Takagi, Y Suzuki Journal of Clinical Oncology 41 (16_suppl), e15011-e15011, 2023 | | 2023 |
| Predicting Response to Immune Checkpoint Inhibitor Therapy: Emerging Role for Artificial Intelligence? P Alerasool, S Zhou, B Tsao, CK Tsao 21st Century Pathology 3 (5), 1-5, 2023 | | 2023 |
